

Title	Roles of the gut virome and mycobiome in faecal microbiota transplantation
Authors	Lam, Siu; Bai, Xiaowu; Shkoporov, Andrey N.; Park, Heekuk; Wu, Xiaojian; Lan, Ping; Zuo, Tao
Publication date	2022-04-06
Original Citation	Lam, S., Bai, X., Shkoporov, A. N., Park, H., Wu, X., Lan, P. and Zuo, T. (2022) 'Roles of the gut virome and mycobiome in faecal microbiota transplantation', <i>The Lancet Gastroenterology &amp; Hepatology</i> , 7(5), pp. 472-484. doi: 10.1016/S2468-1253(21)00303-4
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1016/S2468-1253(21)00303-4
Rights	© 2021, Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC BY-NC-ND 4.0 license. - <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</a>
Download date	2025-02-11 22:09:10
Item downloaded from	<a href="https://hdl.handle.net/10468/13096">https://hdl.handle.net/10468/13096</a>



# UCC

**University College Cork, Ireland**  
 Coláiste na hOllscoile Corcaigh



## 26 **Summary**

27 Faecal microbiota transplantation (FMT) is an innovative approach to treat  
28 diseases associated with a gut dysbiosis, by transferring a healthy stool  
29 microbiota to a diseased recipient. Beyond the bacteriome, the human gut  
30 also harbours diverse communities of viruses and fungi, collectively known  
31 as the virome and the mycobiome. The impact of these latter two microbiome  
32 components on success of FMT therapy has not been appreciated until very  
33 recently. We herein review the current literature on the effects of the gut  
34 virome and mycobiome in the FMT treatment of various diseases. We  
35 discuss both the beneficial effects and health concerns of the viral and fungal  
36 transfer during FMT. We particularly highlight the roles of bacteriophages  
37 (bacterial viruses) and *Candida* species (fungi) in FMT efficacy. We also  
38 summarise the intricate relationships between the gut virome, mycobiome,  
39 bacteriome, and host immunity, underlying FMT. Future efforts should be  
40 devoted to understanding the versatile roles as well as the therapeutic  
41 mechanisms of specific and/or combination of viral and fungal lineages in  
42 different diseases. Harnessing the gut virome, mycobiome, and bacteriome in  
43 combination and precision hold a promising prospect in future FMT- and  
44 microbiota-based therapies.

45

## 46 Introduction

47 A large number of diseases are characterized by compositional and  
48 functional changes in the gut microbiota. Faecal microbiota transplantation  
49 (FMT) is a gut microbiota restoration treatment, performed through oral, intra-  
50 intestinal or intra-colonic administration of donor faecal matter containing  
51 natural microbial consortia. It is well established that the bacterial microbiome  
52 (bacteriome) plays a prominent role in the pathogenesis of gastrointestinal  
53 tract (GI) diseases and affects the outcome of therapies.<sup>1,2</sup> Apart from  
54 bacteriome, the human gut contains diverse and largely under-explored  
55 communities of viruses and fungi.<sup>3,4</sup> Recent evidence suggests that the gut  
56 virome and mycobiome not only constitute a significant fraction of the total  
57 microbiome, but also work in synergy with the bacteriome to modulate host  
58 immunity and physiology.<sup>5,6</sup> Evidence on the roles of gut virome and  
59 mycobiome in FMT outcome is also accumulating.<sup>7-9</sup>

60

61 FMT has garnered substantial clinical and translational research interests.<sup>10,11</sup>  
62 It has broad applications across different diseases, both intra- and extra-  
63 intestinal diseases, including *Clostridioides difficile* infection (CDI), recurrent  
64 CDI (rCDI), inflammatory bowel diseases (IBD), graft versus host disease  
65 (GvHD), irritable bowel syndrome (IBS), obesity and diabetes.<sup>8-10,12-14</sup> While  
66 FMT was previously found comparable with the treatment of probiotics in  
67 efficacy when treating various diseases, it was recently demonstrated that  
68 autologous FMT, but not a multi-strain probiotic product, was effective in  
69 post-antibiotic restoration of microbiome in mice.<sup>15,16</sup> This is likely due to the  
70 fact that FMT transfers a complete and complex consortium of host-adapted  
71 microbial species, including bacteria, bacteriophages, fungi, as well as their  
72 metabolites, as opposed to a greatly simplified multi-strain bacteriotherapy.  
73 The efficacy of FMT has long been ascribed to the transfer of bacteria.<sup>10,11</sup>  
74 Compared to that, the roles of virome and mycobiome are relatively less  
75 studied and are yet to be fully emphasized.<sup>2,6,17-19</sup>

76

77 In this review, we aim to summarise relevant clinical, translational, and basic  
78 research evidence in the field to enhance the community's understanding of  
79 the roles of gut virome and mycobiome in FMT, to inform better clinical  
80 practice by incorporating the viral and fungal components of the gut  
81 microbiome into FMT regime, and in a broader context, to guide future  
82 development of microbiota-based therapies. We will discuss the roles of gut  
83 virome and mycobiome in FMT in conjunction with their functional  
84 importance, donor-recipient effect, as well as safety concerns, and highlight  
85 how they potentially impact treatment efficacy and host immunity during FMT.

86

## 87 **Roles of gut virome in FMT**

### 88 **The human gut virome**

89 The human gut virome is primarily comprised of prokaryotic viruses (mostly  
90 bacteriophages infecting bacteria, collectively known as 'phageome') and  
91 eukaryotic viruses (infecting humans), with bacteriophages of the order  
92 *Caudovirales* (tailed icosahedral viruses with dsDNA genomes) and the  
93 family *Microviridae* (small icosahedral viruses with ssDNA genomes) being  
94 most abundant (figure 1a).<sup>3,20-22</sup> Bacteriophages in the human GI tract have  
95 both temperate and lytic lifecycles, driving the bacteriome composition by  
96 prophage integration and lytic predation respectively.<sup>3,23</sup> Healthy human gut  
97 virome is dominated by temperate bacteriophages, while it shifts from  
98 temperate to lytic replication during host inflammation and stress.<sup>3,24</sup> Given  
99 the predominance of bacteriophages over eukaryotic viruses in the gut  
100 virome and its direct roles in regulating bacteriome composition and function,  
101 most gut virome research in humans has been focusing on the phageome.  
102 While a minority of eukaryotic viruses can cause serious infections, emerging  
103 data on a large diversity of gut-resident eukaryotic viruses show that they are  
104 somewhat capable of recapitulating the beneficial effects of commensal  
105 bacteria through different mechanisms involving host immunity.<sup>25,26</sup>  
106 Eukaryotic viruses can ameliorate gut inflammation in mice via viral RNA  
107 sensing by host Toll-like Receptors (TLRs)-3 and 7 and its downstream IFN-  
108  $\beta$  secretion, and antiviral treatment led to more severe colitis in dextran

109 sulfate sodium (DSS)-treated mice.<sup>27</sup> A recent study in mice also shows that  
110 enteric eukaryotic viruses evoke broad and enduring host immune responses  
111 resembling those elicited by the commensal bacteria.<sup>28</sup> These data suggest  
112 that gut viruses play an important role in host immunity and homeostasis.

113

114 Gut viruses overall constitute a more diverse genetic entity than the gut  
115 bacteria, with virus to microbe ratio (VMR) ranging from 1:1 to 10:1 in the  
116 gut.<sup>29,30</sup> Human gut virome is highly diverse and immensely affected by  
117 geography, ethnicity, diet, lifestyle and age (figure 1a, together accounting for  
118 ~30% of gut virome variations).<sup>31,32</sup> Gut virome dysbiosis has been implicated  
119 in the pathogenesis of a diversity of GI and extra-GI diseases, such as  
120 IBD<sup>21,33</sup>, IBS<sup>34</sup>, CDI<sup>7,35</sup>, GvHD<sup>12,36</sup>, obesity and diabetes<sup>37,38</sup>, and FMT have  
121 demonstrated a varying degree of success in treating these diseases.<sup>7,12,14,39–</sup>  
122 <sup>42</sup> One commonly observed feature of the gut virome alterations in GI  
123 inflammation-related diseases, including in CDI and IBD, is expansion of  
124 *Caudovirales*, which was significantly decreased after FMT.<sup>7,21,33,35,43</sup> In a  
125 DSS-induced colitis model of a mouse colony without colonisation of *E. coli*,  
126 cocktail of *Enterobacteriaceae* bacteriophages, belonging to *Caudovirales*,  
127 exacerbated intestinal inflammation and did not induce lysis of any  
128 endogenous microbes.<sup>43</sup> This study corroborated that *Enterobacteriaceae*  
129 phages alone were sufficient to elicit inflammatory responses without  
130 engagement of *Enterobacteriaceae* or its constituent LPS. These data  
131 highlight the importance of *Caudovirales* bacteriophages in gut homeostasis  
132 and inflammation and that *Caudovirales* can be manipulated by FMT.

133

134

### 135 **Translational studies investigating FMT and virome**

136 Transfer and engraftment of viruses, along with bacteria, during naïve FMT  
137 correlated with treatment outcome in difference diseases, including CDI, IBD,  
138 GvHD following hematopoietic stem cell transplant (HSCT).<sup>7,12,44–47</sup> In a  
139 seminal study conducted by Ott et al, the authors showed that sterile faecal  
140 filtrate (containing viruses, as well as various metabolites and polymers, but

141 not bacteria) was sufficient for successful remission in patients with CDI<sup>48</sup>.  
142 Following that, a number of studies further emphasised the importance of gut  
143 viruses, beyond bacteria, in FMT therapies.<sup>7,14,48,49</sup> In recent years, a handful  
144 of sterile faecal filtrate and faecal viral transplantation (FVT) studies have  
145 emerged investigating the role of gut virome in disease therapeutics,  
146 including obesity, type 2 diabetes (T2D), necrotizing enterocolitis (NEC),  
147 small intestinal bacterial growth, and post-antibiotic microbiome  
148 dysbiosis.<sup>14,49-51</sup>

149

### 150 ***FMT in CDI***

151 The efficacy of FMT in treating CDI is 90%, which is the most promising  
152 compared to its applications in other diseases.<sup>52-56</sup> In our pilot FMT study on  
153 patients with CDI (n=9; FMT was conducted via nasoduodenal infusion of  
154 donor stool from a healthy household individual to each patient), we found  
155 that the gut virome of CDI was characterized by a significant elevation in  
156 *Caudovirales* bacteriophages and a reduced virome diversity compared to  
157 healthy individuals.<sup>7</sup> After FMT, patients showed substantial viral  
158 transmission from donor to recipient.<sup>7</sup> Patients who were cured from CDI  
159 exhibited much higher engraftment rates of *Caudovirales* taxa derived from  
160 the FMT donor, than those who were not responsive to FMT.<sup>7</sup> Recently, a  
161 study on rCDI (n=9) showed that after FMT, the coding genes repertoire of  
162 the patients' gut virome was more similar to that of the donors' compared to  
163 their pre-FMT profiles, including KO (Kyoto encyclopedia genes and  
164 genomes Orthology) terms associated with viral replication, iron transporters,  
165 ssDNA phage assembly, and antimicrobial peptide resistance, paralleling the  
166 changes in their host bacteria after FMT.<sup>35</sup> This data indicates a potential  
167 functionality change in the gut virome of recipient along with the  
168 compositional changes in viral taxa after FMT. Concordantly, several studies  
169 reported that recipient viromes resembled those of their donors and remained  
170 stable after FMT.<sup>7,46,47</sup> Among these studies, one with longer follow-up  
171 showed that patients with CDI (n=14) showed a post-FMT gut virome profile  
172 similar to that of their donors for up to 1 year after FMT.<sup>47</sup>

173

174 **FMT in IBD**

175 The efficacy of FMT in treating IBD varies from ulcerative colitis (UC) to  
176 Crohn's disease (CD). A systematic analysis documented 53 studies that the  
177 overall FMT efficacy is around 36% in UC, 50.5% in CD and 21.5% in  
178 patients with pouchitis.<sup>57</sup> In patients with IBD, the faecal virome displayed  
179 increased richness of *Caudovirales* bacteriophages along with a decreased  
180 bacterial diversity (n=174; patients were from Cambridge, UK; Chicago, Los  
181 Angeles, and Boston, in USA).<sup>21</sup> At the intestinal mucosal level, patients with  
182 UC (n=91; three China cohorts) showed that the rectal tissues consistently  
183 had an expansion of *Caudovirales* bacteriophages compared with healthy  
184 individuals.<sup>33</sup> Phages of *Escherichia* and *Enterobacteria*, belonging to the  
185 order *Caudovirales*, were experimentally demonstrated to aggravate  
186 intestinal inflammation and colitis as a consequence of overproduction of  
187 IFN- $\gamma$  via TLR-9 signalling in the murine host<sup>43</sup>. These data together suggest  
188 that certain *Caudovirales* taxa play a crucial role in the disease course of  
189 IBD. However, the role of the phageome (particularly *Caudovirales*  
190 bacteriophages) in FMT therapies of IBD has not been thoroughly  
191 investigated to date, which warrants in-depth research.

192

193 An increased eukaryotic virome richness was also observed in faeces of  
194 patients with UC.<sup>44</sup> One pilot FMT study in UC patients (n=9) found that UC  
195 individuals who successfully responded to FMT contained a significantly  
196 lower eukaryotic virome richness (both before and after FMT) compared to  
197 non-responders.<sup>44</sup> This study indicates that a low baseline eukaryotic viral  
198 richness might be important for a successful FMT in UC, albeit the  
199 mechanism is lacking. Overall, the role of viral engraftment and virome  
200 alterations in FMT therapies targeting IBD is still in its infancy and represents  
201 an area of particular interest.

202



### 203 ***FMT in GvHD***

204 Limited studies have found some effectiveness of FMT in treating GvHD,  
205 though the overall efficacy is lacking.<sup>12,58</sup> Patients with GvHD following HSCT  
206 manifested significant GI symptoms and showed a persistent dominance of  
207 eukaryotic viruses (anelloviruses, herpesviruses, papillomaviruses and  
208 polyomaviruses) in the gut.<sup>36</sup> Among them, picobirnaviruses were determined  
209 as a predictive marker for the development of severe GvHD.<sup>36</sup> In a single  
210 case study, a GvHD patient was treated with 4 episodes of FMT.<sup>12</sup> Following  
211 treatment, an increase in faecal virome diversity was observed, accompanied  
212 by expansion of *Caudovirales* bacteriophages and shrinkage in the  
213 eukaryotic Torque teno viruses.<sup>12</sup> Consistent with FMT effects on virome  
214 reported in CDI, the transfer of *Caudovirales* bacteriophages also underpins  
215 a positive treatment outcome in GvHD.<sup>7,12</sup> Future research with expanded  
216 sample sizes is needed to convincingly address the therapeutic effect of FMT  
217 and virome modulations in GvHD.<sup>58,59</sup>

218

### 219 ***Faecal viral transplantation (FVT) in other disease indications***

220 As viruses are co-transferred alongside bacteria during naïve FMT, the role  
221 of viruses is fastidious to tease apart from that of bacteria in treating disease.  
222 Two pilot case series studies (n=5 and 4) explored the effect of sterile faecal  
223 filtrate in treating CDI, a refined FMT protocol where the bacteria were filtered  
224 out.<sup>48,60</sup> This study showed that sterile faecal filtrate restored normal stool  
225 habits and eliminated symptoms of CDI, suggesting a possible role of  
226 bacteriophages and viruses (as a prominent component of sterile faecal  
227 filtrate) in the therapeutic mechanism of FMT. However, caution should be  
228 taken when interpreting these studies considering that the biological effect of  
229 sterile faecal filtrate is not solely attributed to the viral microbiota *per se*,  
230 where the metabolites, digested micro-nutrients, extracellular active  
231 ingredients (such as viral envelope, bacterial cell wall components and  
232 antimicrobial peptides) are also present in sterile faecal filtrate.

233

234 Following that, more studies have employed a further refined protocol, FVT,  
235 to specifically investigate the effect of faecal viruses in treating diseases,  
236 where faecal virus-like particle (VLP) are isolated, purified, and enriched.<sup>14,49–</sup>  
237 <sup>51</sup> In a piglet model of preterm infants, Brunse et al. showed that orally  
238 administrated FVT successfully prevented the development of necrotising  
239 enterocolitis (NEC) in all preterm piglets that received FVT, whereas FMT did  
240 not perform better than the control arm, indicating that a gut virome transfer  
241 and modification might be critical in preventing the development of NEC.<sup>50</sup>  
242 Following antibiotic-mediated disruption of the bacteriome in human patients,  
243 rapid restoration of the depleted microbiota might confer significant health  
244 benefits.<sup>49</sup> Probiotics were shown to be not only ineffective in post-antibiotic  
245 restoration of the gut microbiome, but sometimes even leading to impaired  
246 microbiome recovery<sup>15,16</sup>. In contrast to that, a study investigated the effect of  
247 autologous FVT (harvested prior to antibiotics perturbation) in mice reported  
248 a better gut bacteriome recovery after antibiotic perturbation, compared to  
249 the control treatment.<sup>49</sup> More recently, a study reported the effect of FVT in  
250 treatment of type 2 diabetes and obesity in mice.<sup>14</sup> Obese mice treated with  
251 FVT showed improvement in glucose tolerance and reduced further weight  
252 gain caused by high-fat diet.<sup>14</sup> In these mice, FVT was found to impact not  
253 only the virome but also the bacteriome, due to the transfer of  
254 bacteriophages.<sup>14</sup> In addition, FVT can reduce high-fat diet-induced small  
255 intestinal bacterial overgrowth.<sup>51</sup> Taken together, these findings emphasise  
256 the critical role of virome transfer in successful FMT therapies of various  
257 human diseases.

258

### 259 **Donor and recipient effect**

260 In our prior FMT-CDI study, we found that donor-recipient pairs with a higher  
261 faecal viral richness of *Caudovirales* in donor than recipient was predictive of  
262 a better clinical outcome in CDI.<sup>7</sup> This result at the same time was coupled  
263 with changes in the bacteriome, where FMT-driven *Caudovirales* transfer  
264 was positively correlated to the bacterial richness and diversity in the  
265 responders.<sup>7</sup> Due to the co-transfer nature of virome and bacteriome during  
266 FMT, it precludes us separating the effect of virome and that of bacteriome in

267 influencing FMT outcome in this setting. Albeit, it highlights the importance of  
268 donor virome composition and significance of appropriate donor-recipient  
269 pairing for the efficacy of FMT. Consistently, another study found that donors  
270 with a high faecal bacteriophage  $\alpha$ -diversity and a low bacteriophage  
271 abundance were associated with a successful FMT in CDI.<sup>45</sup>

272

273 By adopting a single-cell viral tagging (VT) approach, researchers  
274 investigated whether individual phages isolated from one subject's faeces  
275 could interact with bacteria isolated from a different subject, as a proxy for  
276 FMT.<sup>61,62</sup> They found that a high level of cross-reactivity between  
277 bacteriophages and bacteria from different human subjects, which however  
278 varied across donor-recipient pairs, highlighting a significant donor-recipient  
279 pairing effect on FMT/FVT outcomes.<sup>62</sup> Therefore, by modelling a bacteria–  
280 bacteriophage interaction network between the donor and recipient microbial  
281 communities, based on single-cell VT results, it may become possible to  
282 identify optimal donor-recipient pairs and to predict the outcomes of FMT.

283

#### 284 **Safety concerns of virome transfer in FMT**

285 While data suggests that viral transfer during FMT is an important beneficial  
286 factor for the success of therapy, undesirable viral transmissions constitute a  
287 serious safety concern, especially when transplanting into an  
288 immunocompromised recipient. One report showed that norovirus was  
289 transmitted to 2 out of 13 CDI patients via FMT procedure, who later  
290 developed a post-FMT norovirus gastroenteritis.<sup>63</sup> This report claimed that  
291 viral contamination and transfer during the FMT procedure by a procedure-  
292 involved employee who had previously developed norovirus-like symptoms  
293 might be a cause to the observed post-FMT norovirus gastroenteritis.<sup>63</sup> A  
294 number of pathogenic eukaryotic viruses can potentially be present in the  
295 human gut, including papillomaviruses, herpesviruses, hepatitis viruses,  
296 bocaviruses, enteroviruses, rotaviruses, and sapoviruses.<sup>64</sup> To prevent  
297 potential transfer of pathogenic eukaryotic viruses during FMT, a thorough  
298 faecal virome screening of the donor should be performed to ensure the

299 safety of faecal transplant. Despite such concerns, FVT seems to be  
300 generally safer than FMT due to the removal of intact bacteria, in particular  
301 obligate and opportunistic bacterial pathogens, prior to transplantation. FVT  
302 can also avoid transfer of certain gut commensals with unwanted properties,  
303 which under certain conditions can interact with host physiology exacerbating  
304 disease. Overall, FMT in general has been found to be safe provided that the  
305 donor screening is done adequately as instructed in international guidelines.  
306 Most, if not all, unfortunate cases have been due to sloppy and highly  
307 unacceptable donor screening.

308

309 Bacteriophages targeting gut bacteria can have cascade effects on bystander  
310 bacteria, as demonstrated in gnotobiotic mice.<sup>65,66</sup> Therefore, which gut  
311 bacteria are going to be affected by phage predation during FMT, to what  
312 extent and in what direction, present an unpredictable and daunting  
313 challenge. Equally complex and unpredictable is the subsequent effects of  
314 microbiome manipulations on the overall health of the human host. In  
315 addition, horizontal gene transfer (HGT) from one bacterial strain to another,  
316 mediated by bacteriophages (phage transduction) can be a significant  
317 contributor to dissemination of antibiotic resistance genes, virulence genes  
318 and other unwanted genetic material.<sup>67</sup> A number of bacteriophages encode  
319 toxins (such as diphtheria toxin, Shiga toxin and erythrogenic toxin) that  
320 increase survival and virulence of their bacterial host during lysogenic  
321 conversion.<sup>68,69</sup> FMT may transfer the bacteriophages carrying these toxin  
322 genes to confer a virulent phenotype to the co-resident bacteriome in the gut  
323 of the recipient, posing another health concern.

324

325 Administering rats with a bacteriophage cocktail led to an increased intestinal  
326 permeability, weight loss, and decreased activity.<sup>70</sup> This study demonstrates  
327 that increased intestinal permeability may be induced by bacteriophages that  
328 affect the microbiota. Recently, a temperate filamentous bacteriophage was  
329 found to integrate into the genome of a multidrug-resistant *Pseudomonas*  
330 *aeruginosa*, resulting in inappropriate antiviral immune responses and

331 impaired clearance of bacterial infection in the host.<sup>71</sup> These evidence  
332 suggest that akin to the transfer of certain eukaryotic viruses, the transfer of  
333 unwanted bacteriophages may also confer undesired health concerns to the  
334 human host.

335

### 336 **Mechanisms of virome function underlying FMT**

337 The mechanisms of viral action contributing to FMT therapies include  
338 tripartite mutualistic interactions between bacteriophages/eukaryotic viruses,  
339 bacteria, and the mammalian host (figure 1b).<sup>6</sup>

340

#### 341 ***Functions of bacteriophages colonisation***

342 Bacteriophage transfer engraftment can modulate not only the taxonomic  
343 composition but also the functional capacity of the gut bacteriome.<sup>65,66,72</sup>  
344 Faecal multi-omics profiling of mice receiving a transplant of a defined  
345 consortium of bacteriophages revealed shifts in both the microbiome and gut  
346 metabolome after bacteriophage colonisation.<sup>66</sup> The result showed that a  
347 large diversity of metabolites was altered after bacteriophage transplantation,  
348 including nearly all KEGG pathways (amino acids, peptides, carbohydrates,  
349 lipids, nucleotides, cofactors, vitamins, and xenobiotics).<sup>66</sup> A recent study  
350 also showed that *Bacteroides* phage BV01 altered the genome-wide  
351 transcriptome profiles and bile salt hydrolase activity in its bacterial host,  
352 leading to an altered profile of bile acids.<sup>72</sup> In return, bile acids are well known  
353 to regulate both host microbiome (including *C. difficile*) and host  
354 physiology.<sup>73,74</sup> Such changes in gut bacteriome composition and functionality  
355 induced by bacteriophage colonisation are important for host health.

356

357 Accumulating data suggest that bacteriophages can modulate the immune  
358 system both directly and indirectly. Indeed, bacteriophages can colonise the  
359 intestinal mucus layer, directly binding to mucin glycoproteins via their  
360 capsids, and provide the mammalian host with a defence mechanism against  
361 the bacteria trying to breach through the intestinal barrier.<sup>75</sup> Certain

362 bacteriophages, such as phage 536\_P1, directly promote the production of  
363 antiviral cytokines, such as IFN- $\gamma$  and IL-12, as well as chemokines, even in  
364 the absence of their host bacteria.<sup>76</sup> Bacteriophages can interact with the  
365 host immune system in various ways, by inducing the innate defenses  
366 against bacterial colonisation, stimulating production of inflammatory  
367 cytokines, and activating dendritic cells (DCs) and innate lymphoid cells  
368 (ILCs) to produce IFNs (figure 1b).<sup>77</sup>

369

### 370 ***Functions of eukaryotic viruses colonisation***

371 In addition, colonisation with eukaryotic viruses in the gut is critical for the  
372 maintenance of gut microbial homeostasis and host immunity. Recognition of  
373 the bulk of enteric viruses via surface receptors TLR3 or TLR7 induces  
374 production of IFN- $\beta$ , which protects the host from developing inflammation.<sup>27</sup>  
375 The RIG-I receptor for viral RNA recognition in the cytosol signals IL-15  
376 production to maintain homeostasis of intraepithelial lymphocytes.<sup>78</sup> Another  
377 prime example of protective effects of intestinal eukaryotic virome was  
378 demonstrated in murine norovirus (MNV)-colonised mice.<sup>79</sup> The viral protein  
379 NS1/2 from MNV evoked a host protective response with increased  
380 production of IFN-I and IL-22, which conferred a critical protection against  
381 *Citrobacter rodentium* infection and promoted proliferation of the intestinal  
382 epithelial cells.<sup>79</sup> A recent comprehensive murine study profiled the immune  
383 responses to a panel of eukaryotic viruses and found a widespread capacity  
384 for asymptomatic intestinal colonisation and durable alterations that the both  
385 strain-specific and common to multiple viruses.<sup>28</sup> Most enteric viruses  
386 promoted T cell differentiation, Th1 polarization, and production of IL-22, a  
387 cytokine central to the dialog between host and microbiome at epithelial  
388 barriers.<sup>28,80</sup> Such enteric viruses could transcriptionally upregulate anti-  
389 bacterial peptides, though to a lesser extent than a consortium of 15 bacterial  
390 strains in germ-free (GF) mice.<sup>28</sup> In addition, astrovirus supplementation in  
391 immunocompromised mice can protect the mice from enteric pathogens via  
392 IFN- $\lambda$ , transferable by cohousing and faecal transplantation.<sup>81</sup> These data  
393 together suggest that gut eukaryotic viruses also tune host homeostasis by  
394 orchestrating both the host immunity and the co-resident microbiome.

395

396 Taken together, these studies indicate that colonisation by gut viruses, both  
397 prokaryotic and eukaryotic, is essential to calibrate host immunity and  
398 physiology. Transfer and engraftment of gut viruses via FMT can have broad  
399 cascading effects on the mammalian host, including modulation of host  
400 microbiome, metabolome, and immunity.

401

## 402 **Roles of gut mycobiome in FMT**

### 403 **The human gut mycobiome**

404 The human GI tract is also home to a large diversity of fungi, collectively  
405 known as the gut mycobiome. Fungi constitute a minor component of the gut  
406 microbiota, making up approximately 0.1% of the microorganisms shown by  
407 metagenomics sequencing.<sup>4,82,83</sup> Studies have shown that the gut harbours  
408 >50 genera of fungi with *Candida*, *Saccharomyces*, *Cladosporium* and  
409 *Malassezia* being the most abundant genera (figure 2a).<sup>4,82,83</sup> However, the  
410 gut fungi are highly under-explored relative to the gut bacteria, and hence are  
411 underrepresented in current mycobiome databases, hindering gut  
412 mycobiome profiling and functional characterisation.<sup>84</sup> Gut resident fungi  
413 have both mutualistic and antagonistic relationships with the gut bacteria,  
414 together shaping the host immunity.<sup>85</sup> Intestinal fungi have been shown to be  
415 causally implicated in microbiome assembly and immune development.<sup>86</sup>  
416 Accumulating evidence points to that the gut mycobiota can strongly  
417 influence the host immune system and this interaction is linked to bacteria  
418 activities.<sup>87,88</sup> Recent observations of dysbiosis in gut mycobiome across  
419 various diseases highlight a critical role of gut fungi in disease  
420 pathogenesis<sup>89–91</sup>, suggesting that targeting gut mycobiome may represent a  
421 promising therapeutic modality.

422

### 423 **Translational studies investigating FMT and mycobiome**

424 Emerging studies report that FMT involves transfer of fungi, which may affect  
425 treatment outcomes.<sup>8,9</sup> Our FMT-fungi study in CDI (n=16) showed that donor

41

42

426 fungi were substantially transferred to recipient after FMT, and cure after  
427 FMT was associated with increased colonisation of donor-derived fungal taxa  
428 in recipients.<sup>8</sup> After FMT, responders displayed a high relative abundance of  
429 *Saccharomyces* and *Aspergillus*, whereas non-responders and patients  
430 treated with antibiotics displayed a dominant presence of *Candida* in faeces.<sup>8</sup>  
431 CDI patients who responded to the treatment showed a reduction in the  
432 abundance of *C. albicans* after FMT, while those who did not respond to FMT  
433 showed a still high abundance of *C. albicans* in faeces.<sup>8</sup> In favor of this  
434 finding in humans, we observed that *C. albicans* also negated FMT efficacy  
435 in a mouse model of CDI.<sup>8</sup> In a separate experiment, we showed that  
436 antifungal treatment to eliminate *C. albicans* in recipient mice before FMT re-  
437 established FMT efficacy using the same donor stool without presence of *C.*  
438 *albicans*.<sup>8</sup> These evidence together highlight a causal relationship between  
439 gut fungal dysbiosis and FMT outcome in CDI.

440

441 Interestingly, a recent FMT study conducted in patients with UC (n=24)  
442 observed a different association between faecal *C. albicans* levels and  
443 treatment outcome: UC patients with higher *C. albicans* abundance pre-FMT  
444 were much likely responsive to FMT.<sup>9</sup> On the other hand, in agreement with  
445 the finding in CDI, FMT resulted in a reduction of *C. albicans* in UC patients.<sup>9</sup>  
446 Decreased *Candida* abundance post-FMT was indicative of ameliorated UC  
447 severity.<sup>9</sup> These findings suggest that FMT reduces *C. albicans* abundance,  
448 and a decreased *C. albicans* abundance after FMT is associated with  
449 disease amelioration in both CDI and UC. The discordant findings between  
450 CDI and UC that a high faecal abundance of *C. albicans* in recipients pre-  
451 FMT may lead to discrepant treatment outcomes after FMT underscores that  
452 gut fungi in recipient baseline may affect FMT efficacy in a disease-  
453 dependent manner. Similarly, patients with CD had higher fungal burden and  
454 *Candida* colonisation in the gut, however CD patients were less responsive to  
455 FMT compared to UC.<sup>10,92-94</sup> Different immunophysiology and  
456 immunopathophysiology mechanisms, though calibrated by the same fungi,  
457 in different disease settings may underlie this discordance in FMT efficacy  
458 between diseases.



459

460 Overall, FMT treatment is able to reduce *C. albicans* levels in recipient and  
461 produce a positive treatment outcome in CDI and IBD. This effect is also  
462 evidenced in different mouse models, demonstrating that FMT prevented *C.*  
463 *albicans* colonisation.<sup>8,95,96</sup> In a pilot study, a patient with UC was cleared of  
464 recurrent *C. glabrata* infection after FMT<sup>97</sup>, suggesting FMT may be able to  
465 deliver a possible beneficial effect on patients who are complicated with  
466 fungal infection. Another clinical study showed that FMT was effective to  
467 reduce the likelihood of developing blood stream fungal infection in rCDI  
468 patients compared to antibiotics treatment.<sup>98</sup> These studies further support  
469 that FMT is capable of modulating recipient fungi, including *Candida* species.

470

471 Another intestinal disorder IBS is also characterised by a significant alteration  
472 in the gut mycobiome, featured by predominance of two fungal species *C.*  
473 *albicans* and *Saccharomyces cerevisiae* compared to healthy individuals.<sup>99</sup>  
474 Interestingly, IBS-related visceral hypersensitivity was transferable between  
475 rats by FMT, suggesting a causal role of gut microbiome in IBS.<sup>99</sup> To date,  
476 whether FMT is effective in IBS is still controversial in clinical practices. One  
477 randomized clinical trial (n=90) conducted in a cohort of IBS patients in  
478 northern Norway showed that FMT relieved IBS symptoms compared to the  
479 placebo arm, whereas another randomized clinical trial (n=48) conducted in  
480 three US centres showed that FMT was ineffective in reducing IBS symptoms  
481 compared with placebo.<sup>100</sup> Whether gut fungi play a role in such  
482 heterogenous clinical efficacy of FMT in IBS warrants further investigation.

483

484 FMT is a promising agent for treating infectious diseases and gastrointestinal  
485 disorders, it has been utilised for treating severe colitis in GvHD patients  
486 following allogenic HSCT.<sup>12</sup> The antifungal drug fluconazole has been shown  
487 to prevent *C. albicans* colonisation and to reduce the likelihood of developing  
488 GvHD after HSCT, suggesting that modulation of gut mycobiota may be  
489 associated with the pathogenesis of GvHD post HSCT.<sup>101</sup> More recently, our  
490 observational FMT study on a single GvHD case reported some changes in

491 the gut mycobiome following a successful treatment of 4-dose FMT.<sup>12</sup> The  
492 serial FMT treatments altered the fungal composition and diversity in the  
493 faeces of this GvHD patient, which was more similar to the donor's faecal  
494 fungal profile after FMT compared to his pre-FMT profile.<sup>12</sup> However, as this  
495 pilot study was exploratory, an expanded sample size is needed in future to  
496 address any biologically meaningful changes in recipient's gut mycobiome by  
497 FMT underlying cure of GvHD.

498

499 The role of gut mycobiome in FMT is elusive and there is a significant lack of  
500 human and animal studies centered on fungal transfer in FMT treating  
501 different diseases. The keystone fungal species as well as their functions in  
502 the gut and FMT remain to be discovered in different disease settings.

503

#### 504 **Donor and recipient effect**

505 As aforementioned, our FMT-CDI study in both humans and mice found that  
506 existence of *C. albicans* in donor and high abundance existence of *C.*  
507 *albicans* in CDI recipient pre-FMT were both detrimental to FMT outcome.<sup>8</sup>  
508 Similarly, two filamentous fungi *Penicillium brocae* and *Aspergillus*  
509 *penicillioides*, present in either donor or recipient pre-FMT, also nullified the  
510 treatment efficacy of FMT in CDI mice, highlighting a generic deleterious role  
511 of overrepresentation of certain fungi in donor or recipient in FMT.<sup>8</sup> Antibiotics  
512 are always the primary treatment for patients with CDI, which may lead to a  
513 fungal bloom and a high likelihood of developing fungal infections in patients,  
514 particularly expansion of *Candida* species.<sup>102</sup> These data underscores the  
515 importance of donor selection (exclusion of invasive *Candida* carriers) and  
516 appropriate recipient preparation based on their faecal fungal profiles, to  
517 enhance FMT efficacy in CDI. In contrast, a high faecal abundance of *C.*  
518 *albicans* in UC patients pre-FMT was associated with a favourable FMT  
519 outcome.<sup>9</sup> Taken together, it suggests that the gut mycobiome composition of  
520 donor and recipient should be considered separately in different disease  
521 settings when employing FMT.

522

**523 Safety concerns of mycobiome transfer in FMT**

524 Analogous to gut bacteria, a lot of gut fungi are opportunistic species which  
525 can mount detrimental immune responses in the host under non-homeostatic  
526 conditions, including *C. albicans*. Therefore, to avoid transfer of fungal  
527 pathogens and opportunistic fungal pathogens, thorough donor screening  
528 based on the faecal fungal profile is necessary during FMT practice. To date,  
529 there has no report of death or infection caused by transmission of life-  
530 threatening fungi from FMT, but screening for fungal candidates in the donor  
531 and susceptible recipients should also be cautious. Fungal infection is often  
532 seen in immunocompromised patients with CDI, IBD and GvHD, and the  
533 responsible candidates are *Candida* species that contribute to the majority of  
534 infections.<sup>97,98,101</sup> Most common fungal infections in CDI are caused by *C.*  
535 *albicans*, *C. parapsilosis*, and *C. tropicalis* in the blood stream due to  
536 prolonged use of antibiotics.<sup>98</sup> These fungi constitute a health concern to the  
537 host, and may nullify FMT efficacy and invoke undesired immune responses  
538 after FMT.

539

540 Other fungi, such as *Malassezia restricta* and *Histoplasma capsulatum*  
541 should also be checked in donor screening.<sup>103,104</sup> *M. restricta* is a skin  
542 commensal that preferentially colonises in CD patients with CARD9  
543 polymorphism, whereas *H. capsulatum* preferentially infects IBD patients with  
544 immunocompromised condition.<sup>103,104</sup> CARD9 and dectin-1 are well known  
545 fungal recognition receptors, and polymorphisms in these genetic loci are  
546 associated with increasing susceptibility to fungal infections.<sup>105-107</sup> It is known  
547 that antibiotics can alter the gut bacterial-fungal community structure and that  
548 antibiotics treatment was found to offer longer-lasting impact on gut fungi  
549 other than bacteria.<sup>108</sup> Hence, fungal profiling in the donor, the genetically  
550 susceptible or immunosuppressive recipient, as well as those with a drug or  
551 antibiotics history, are needed to avoid potential fungal bloom or infection  
552 following FMT.<sup>105-107,109</sup>

553

## 554 **Mechanisms of protective immunity elicited by the gut fungi**

555 The commensal fungi in the gut can evoke protective immunity in the host  
556 and impact gut microbiome assembly.<sup>6,88,105,110,111</sup> The mechanisms of  
557 mycobiome action underlying FMT treatment of diseases hence also involve  
558 a tripartite interaction between fungi, bacteria, and the mammalian host  
559 (figure 2b).

560

561 It is shown in gnotobiotic mice that commensal fungi can functionally  
562 recapitulate the protective benefits of intestinal commensal bacteria, by  
563 mitigating tissue injury and extra-intestinal infection as well as calibrating the  
564 activation of protective CD8+ T cells.<sup>112</sup> Elimination of the gut fungi by oral  
565 antifungals in mice worsened the outcome of colitis and allergic airway  
566 disease<sup>91</sup>, where both the host immune profile and the gut bacteriome  
567 composition were disrupted, suggesting that colonisation of gut commensal  
568 fungi plays an import role in host immune and microbiome homeostasis.  
569 Fungi can stimulate host cells through a variety of microbial pattern  
570 recognition receptors (PRRs).<sup>6,105,110,113–117</sup> Surface receptors, such as dectin-  
571 1, dectin-2, mincle and CX3CR1 receptors on mononuclear phagocytes  
572 (MNs) can recognize  $\beta$ -glucans in the fungal cell wall.<sup>6,105,110,113–117</sup> Fungal  
573 sensing by CARD9 signalling induces release of IL-18 for reconstitution of  
574 intestinal epithelial cells (IECs).<sup>6,105,110,113,118</sup> IL-22 elicited by fungal sensing  
575 restricts inflammasome from triggering immune pathology.<sup>119</sup> Fungal-derived  
576 molecules and metabolites, such as mannans and glucans, are also critical  
577 components to calibrate host immunity by changing the cytokine profile.<sup>120,121</sup>  
578 These mechanistic studies underscore the sophisticated molecular pathways  
579 underlying gut fungi regulating host immunity.

580

581 Another aspect of mycobiome function on the host is its interactions with gut  
582 bacteria and other co-resident fungi. In steady state, bacteria and fungi keep  
583 each other in check in the gut. One study demonstrated that *C. albicans*  
584 affects the recolonisation of the cecum by the microbiota in mice treated with  
585 antibiotics.<sup>122</sup> The presence of *C. albicans* in the gut increased colonisation

586 by the bacterium *Enterococcus faecalis* and reduced colonisation of probiotic  
587 *Lactobacillus* strains.<sup>122</sup> A follow-up study revealed that antibiotic-treated *C.*  
588 *albicans*-colonised mice had reduced expression of specific immune genes,  
589 hinting at dual role of *C. albicans* on host immunity and bacteriome  
590 assembly.<sup>123</sup> Several studies have shown that *Saccharomyces boulardii* can  
591 suppress *C. difficile* by the production of a protease to degrade toxins A and  
592 B of *C. difficile*.<sup>124,125</sup> These studies imply that colonisation of *Saccharomyces*  
593 species by FMT may favour a positive outcome in CDI. Moreover, *S.*  
594 *boulardii* has a protective effect against various other bacterial  
595 gastrointestinal pathogens, including *Helicobacter pylori*, *Vibrio cholerae*,  
596 *Salmonella enterica serovar Typhimurium*, *Shigella flexneri*, and *Escherichia*  
597 *coli*.<sup>85</sup> Both *E. coli* and *S. Typhimurium* bind to the surface of *S. boulardii*,  
598 potentially preventing adhesion to intestinal epithelial cells and thus allowing  
599 quicker excretion through faecal matter.<sup>126,127</sup> *S. boulardii* was found to  
600 suppress colonisations of both *C. albicans* and Adherent-invasive  
601 *Escherichia coli* (AIEC) and to alleviate colitis in mice.<sup>128-130</sup> Overall, FMT is  
602 able to cause a collection of fungi colonised in recipient, where they  
603 individually or together with gut bacteria regulate host immunophysiology  
604 influencing FMT outcome.

605

## 606 Conclusions

607 A large body of studies demonstrated efficacy of FMT in re-shaping the  
608 microbial composition and function in the recipients in a number of human  
609 diseases, though resolution of symptoms and cure can only be consistently  
610 achieved in CDI and inconsistently achieved in other diseases, such as IBS,  
611 IBD and obesity. Successful FMT is not only ascribed to the restoration of  
612 healthy gut bacteriome, but also involves modulation of the virome and  
613 mycobiome. The intricate relationships between the bacteriome, the virome  
614 and the mycobiome on one hand, and the human host on the other, underpin  
615 clinical and microbiological effects, and overall efficacy of FMT. Enhanced  
616 understanding of gut virome and mycobiome will guide and facilitate future  
617 precision FMT-based therapies of various human diseases. Well-designed

618 clinical trials based on targeted bacterial-, viral/phage- and fungal-transfer will  
619 be required, so are preclinical mechanistic studies investigating functions of  
620 the individual components of the microbiome. Of particular interest are  
621 different lineages and combinations of *Caudovirales* phages, as well as fungi  
622 from the genera *Candida* and *Saccharomyces*, due to their possible  
623 contributions to FMT efficacy. Precision FMT should be adopted in future,  
624 including FVT and/or defined consortia of phages-fungi-bacteria  
625 combinations, in a personalised, disease-specific manner. We look forward  
626 with optimism to the future of precision FMT, as it transfers a holistic, tailor-  
627 made, and well donor-recipient paired microbiome for disease treatment.

628

## 629 **Search strategy and selection criteria**

630 A literature search was performed on Pubmed, Google Scholar and Web of  
631 Science using the keywords “Faecal microbiota transplantation”, “FMT”,  
632 “Faecal viral transfer”, “FVT”, “Fungal microbiota”, “Gut virus”, “Virome”, “Gut  
633 fungi” and “Mycobiome” to select relevant clinical and animal studies.

634

### 635 **Contributors:**

636 TZ conceived the manuscript. TZ and SL wrote the manuscript. ANS, PL and XJW  
637 provided significant intellectual contribution and edited the manuscript. TZ, PL and  
638 XJW supervised this study. HP and XWB provided critical comments.

639

### 640 **Declaration of interests:**

641 The authors declare no conflict of interest.

642

### 643 **Acknowledgements:**

644 TZ is supported by National Natural Science Foundation of China (NSFC), a seed  
645 fund for center for faecal microbiota transplantation research from the sixth affiliated  
646 hospital of Sun Yat-sen University, and a joint seed fund from the sixth affiliated  
647 hospital of Sun Yat-sen University and Sun Yat-sen University. ANS is supported by  
648 Wellcome Trust Research Career Development Fellowship 220646/Z/20/Z. Figures  
649 were adapted and created via BioRender.com.

650

651

652 **References**

- 653 1 David LA, Maurice CF, Carmody RN, *et al.* Diet rapidly and reproducibly  
654 alters the human gut microbiome. *Nature* 2014; **505**: 559–63.
- 655 2 Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in  
656 Pathogenesis of Inflammatory Bowel Diseases and Therapeutic  
657 Approaches. *Gastroenterology* 2017; **152**: 327-339.e4.
- 658 3 Shkoporov AN, Hill C. Bacteriophages of the Human Gut: The “Known  
659 Unknown” of the Microbiome. *Cell Host Microbe* 2019; **25**: 195–209.
- 660 4 Hoffmann C, Dollive S, Grunberg S, *et al.* Archaea and Fungi of the  
661 Human Gut Microbiome: Correlations with Diet and Bacterial Residents.  
662 *PLoS ONE* 2013; **8**: e66019.
- 663 5 Richard ML, Sokol H. The gut mycobiota: insights into analysis,  
664 environmental interactions and role in gastrointestinal diseases. *Nat Rev*  
665 *Gastroenterol Hepatol* 2019; : 1.
- 666 6 Iliev ID, Cadwell K. Effects of Intestinal Fungi and Viruses on Immune  
667 Responses and Inflammatory Bowel Diseases. *Gastroenterology* 2021;  
668 **160**: 1050–66.
- 669 7 Zuo T, Wong SH, Lam K, *et al.* Bacteriophage transfer during faecal  
670 microbiota transplantation in *Clostridium difficile* infection is associated  
671 with treatment outcome. *Gut* 2017; : gutjnl-2017-313952.
- 672 8 Zuo T, Wong SH, Cheung CP, *et al.* Gut fungal dysbiosis correlates with  
673 reduced efficacy of fecal microbiota transplantation in *Clostridium difficile*  
674 infection. *Nat Commun* 2018; **9**. DOI:10.1038/s41467-018-06103-6.
- 675 9 Leonardi I, Paramsothy S, Doron I, *et al.* Fungal Trans-kingdom Dynamics  
676 Linked to Responsiveness to Fecal Microbiota Transplantation (FMT)  
677 Therapy in Ulcerative Colitis. *Cell Host Microbe* 2020; **27**: 823-829.e3.
- 678 10 Paramsothy S, Kamm MA, Kaakoush NO, *et al.* Multidonor intensive  
679 faecal microbiota transplantation for active ulcerative colitis: a randomised  
680 placebo-controlled trial. *The Lancet* 2017; **389**: 1218–28.
- 681 11 Danne C, Rolhion N, Sokol H. Recipient factors in faecal microbiota  
682 transplantation: one stool does not fit all. *Nat Rev Gastroenterol Hepatol*  
683 2021; published online April 27. DOI:10.1038/s41575-021-00441-5.
- 684 12 Zhang F, Zuo T, Yeoh YK, *et al.* Longitudinal dynamics of gut  
685 bacteriome, mycobiome and virome after fecal microbiota transplantation  
686 in graft-versus-host disease. *Nat Commun* 2021; **12**: 65.
- 687 13 Halkjær SI, Christensen AH, Lo BZS, *et al.* Faecal microbiota  
688 transplantation alters gut microbiota in patients with irritable bowel  
689 syndrome: results from a randomised, double-blind placebo-controlled  
690 study. *Gut* 2018; **67**: 2107–15.



- 691 14 Rasmussen TS, Mentzel CMJ, Kot W, *et al.* Faecal virome  
692 transplantation decreases symptoms of type 2 diabetes and obesity in a  
693 murine model. *Gut* 2020; **69**: 2122–30.
- 694 15 Suez J, Zmora N, Zilberman-Schapira G, *et al.* Post-Antibiotic Gut  
695 Mucosal Microbiome Reconstitution Is Impaired by Probiotics and  
696 Improved by Autologous FMT. *Cell* 2018; **174**: 1406-1423.e16.
- 697 16 Zmora N, Zilberman-Schapira G, Suez J, *et al.* Personalized Gut  
698 Mucosal Colonization Resistance to Empiric Probiotics Is Associated with  
699 Unique Host and Microbiome Features. *Cell* 2018; **174**: 1388-1405.e21.
- 700 17 Li XV, Leonardi I, Iliev ID. Gut Mycobiota in Immunity and  
701 Inflammatory Disease. *Immunity* 2019; **50**: 1365–79.
- 702 18 Lewis JD, Chen EZ, Baldassano RN, *et al.* Inflammation, Antibiotics,  
703 and Diet as Environmental Stressors of the Gut Microbiome in Pediatric  
704 Crohn's Disease. *Cell Host Microbe* 2015; **18**: 489–500.
- 705 19 Kazemian N, Ramezankhani M, Sehgal A, *et al.* The trans-kingdom  
706 battle between donor and recipient gut microbiome influences fecal  
707 microbiota transplantation outcome. *Sci Rep* 2020; **10**: 18349.
- 708 20 Reyes A, Haynes M, Hanson N, *et al.* Viruses in the faecal microbiota  
709 of monozygotic twins and their mothers. *Nature* 2010; **466**: 334–8.
- 710 21 Norman JM, Handley SA, Baldrige MT, *et al.* Disease-Specific  
711 Alterations in the Enteric Virome in Inflammatory Bowel Disease. *Cell*  
712 2015; **160**: 447–60.
- 713 22 Lim ES, Zhou Y, Zhao G, *et al.* Early life dynamics of the human gut  
714 virome and bacterial microbiome in infants. *Nat Med* 2015; **21**: 1228–34.
- 715 23 Guerin E, Hill C. Shining Light on Human Gut Bacteriophages. *Front*  
716 *Cell Infect Microbiol* 2020; **10**: 481.
- 717 24 Clooney AG, Sutton TDS, Shkoporov AN, *et al.* Whole-Virome  
718 Analysis Sheds Light on Viral Dark Matter in Inflammatory Bowel Disease.  
719 *Cell Host Microbe* 2019; published online Nov.  
720 DOI:10.1016/j.chom.2019.10.009.
- 721 25 Kernbauer E, Ding Y, Cadwell K. An enteric virus can replace the  
722 beneficial function of commensal bacteria. *Nature* 2014; **516**: 94–8.
- 723 26 Duerkop BA, Hooper LV. Resident viruses and their interactions with  
724 the immune system. *Nat Immunol* 2013; **14**: 654–9.
- 725 27 Yang J-Y, Kim M-S, Kim E, *et al.* Enteric Viruses Ameliorate Gut  
726 Inflammation via Toll-like Receptor 3 and Toll-like Receptor 7-Mediated  
727 Interferon- $\beta$  Production. *Immunity* 2016; **44**: 889–900.

- 728 28 Dallari S, Heaney T, Rosas-Villegas A, *et al.* Enteric viruses evoke  
729 broad host immune responses resembling those elicited by the bacterial  
730 microbiome. *Cell Host Microbe* 2021; **29**: 1014-1029.e8.
- 731 29 Ogilvie LA, Jones BV. The human gut virome: a multifaceted majority.  
732 *Front Microbiol* 2015; **6**. DOI:10.3389/fmicb.2015.00918.
- 733 30 Mirzaei MK, Maurice CF. Ménage à trois in the human gut:  
734 interactions between host, bacteria and phages. *Nat Rev Microbiol* 2017;  
735 **15**: 397–408.
- 736 31 Zuo T, Sun Y, Wan Y, *et al.* Human-Gut-DNA Virome Variations  
737 across Geography, Ethnicity, and Urbanization. *Cell Host Microbe* 2020;  
738 **28**: 741-751.e4.
- 739 32 Gregory AC, Zablocki O, Zayed AA, Howell A, Bolduc B, Sullivan MB.  
740 The Gut Virome Database Reveals Age-Dependent Patterns of Virome  
741 Diversity in the Human Gut. *Cell Host Microbe* 2020; **28**: 724-740.e8.
- 742 33 Zuo T, Lu X-J, Zhang Y, *et al.* Gut mucosal virome alterations in  
743 ulcerative colitis. *Gut* 2019; : gutjnl-2018-318131.
- 744 34 Coughlan S, Das A, O’Herlihy E, Shanahan F, O’Toole PW, Jeffery IB.  
745 The gut virome in Irritable Bowel Syndrome differs from that of controls.  
746 *Gut Microbes* 2021; **13**: 1–15.
- 747 35 Fujimoto K, Kimura Y, Allegretti JR, *et al.* Functional Restoration of  
748 Bacteriomes and Viromes by Fecal Microbiota Transplantation.  
749 *Gastroenterology* 2021; **160**: 2089-2102.e12.
- 750 36 Legoff J, Resche-Rigon M, Bouquet J, *et al.* The eukaryotic gut virome  
751 in hematopoietic stem cell transplantation: new clues in enteric graft-  
752 versus-host disease. *Nat Med* 2017; **23**: 1080–5.
- 753 37 Park A, Zhao G. Mining the Virome for Insights into Type 1 Diabetes.  
754 *DNA Cell Biol* 2018; **37**: 422–5.
- 755 38 Yang K, Niu J, Zuo T, *et al.* Alterations in the gut virome in obesity and  
756 type 2 diabetes mellitus. *Gastroenterology* 2021; **0**.  
757 DOI:10.1053/j.gastro.2021.06.056.
- 758 39 Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging  
759 applications. *Nat Rev Gastroenterol Hepatol* 2012; **9**: 88–96.
- 760 40 Weingarden AR, Vaughn BP. Intestinal microbiota, fecal microbiota  
761 transplantation, and inflammatory bowel disease. *Gut Microbes* 2017; **8**:  
762 238–52.
- 763 41 Myneedu K, Deoker A, Schmulson MJ, Bashashati M. Fecal  
764 microbiota transplantation in irritable bowel syndrome: A systematic review  
765 and meta-analysis. *United Eur Gastroenterol J* 2019; **7**: 1033–41.

- 766 42 Yu EW, Gao L, Stastka P, *et al.* Fecal microbiota transplantation for  
767 the improvement of metabolism in obesity: The FMT-TRIM double-blind  
768 placebo-controlled pilot trial. *PLoS Med* 2020; **17**.  
769 DOI:10.1371/journal.pmed.1003051.
- 770 43 Gogokhia L, Buhrke K, Bell R, *et al.* Expansion of Bacteriophages Is  
771 Linked to Aggravated Intestinal Inflammation and Colitis. *Cell Host Microbe*  
772 2019; **25**: 285-299.e8.
- 773 44 Conceição-Neto N, Deboutte W, Dierckx T, *et al.* Low eukaryotic viral  
774 richness is associated with faecal microbiota transplantation success in  
775 patients with UC. *Gut* 2018; **67**: 1558–9.
- 776 45 Park H, Laffin MR, Jovel J, *et al.* The success of fecal microbial  
777 transplantation in *Clostridium difficile* infection correlates with  
778 bacteriophage relative abundance in the donor: a retrospective cohort  
779 study. *Gut Microbes* 2019; **10**: 676–87.
- 780 46 Draper LA, Ryan FJ, Smith MK, *et al.* Long-term colonisation with  
781 donor bacteriophages following successful faecal microbial transplantation.  
782 *Microbiome* 2018; **6**: 220.
- 783 47 Broecker F, Klumpp J, Moelling K. Long-term microbiota and virome in  
784 a Zürich patient after fecal transplantation against *Clostridium difficile*  
785 infection: *Clostridium difficile* , fecal transplant, and virome. *Ann N Y Acad*  
786 *Sci* 2016; **1372**: 29–41.
- 787 48 Ott SJ, Waetzig GH, Rehman A, *et al.* Efficacy of Sterile Fecal Filtrate  
788 Transfer for Treating Patients With *Clostridium difficile* Infection.  
789 *Gastroenterology* 2017; **152**: 799-811.e7.
- 790 49 Draper LA, Ryan FJ, Dalmaso M, *et al.* Autochthonous faecal viral  
791 transfer (FVT) impacts the murine microbiome after antibiotic perturbation.  
792 *BMC Biol* 2020; **18**: 173.
- 793 50 Brunse A, Deng L, Pan X, *et al.* Fecal filtrate transfer protects against  
794 necrotizing enterocolitis in preterm pigs. *Microbiology*, 2020  
795 DOI:10.1101/2020.05.25.114751.
- 796 51 Lin DM, Koskella B, Ritz NL, Lin D, Carroll-Portillo A, Lin HC.  
797 Transplanting Fecal Virus-Like Particles Reduces High-Fat Diet-Induced  
798 Small Intestinal Bacterial Overgrowth in Mice. *Front Cell Infect Microbiol*  
799 2019; **9**: 348.
- 800 52 Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota  
801 transplantation for *Clostridium difficile* infection: systematic review and  
802 meta-analysis. *Am J Gastroenterol* 2013; **108**: 500–8.
- 803 53 Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation  
804 for the treatment of *Clostridium difficile* infection: a systematic review. *J*  
805 *Clin Gastroenterol* 2014; **48**: 693–702.

- 806 54 Drekonja D, Reich J, Gezahegn S, *et al.* Fecal Microbiota  
807 Transplantation for *Clostridium difficile* Infection: A Systematic Review.  
808 *Ann Intern Med* 2015; **162**: 630–8.
- 809 55 Cammarota G, Masucci L, Ianiro G, *et al.* Randomised clinical trial:  
810 faecal microbiota transplantation by colonoscopy vs. vancomycin for the  
811 treatment of recurrent *Clostridium difficile* infection. *Aliment Pharmacol*  
812 *Ther* 2015; **41**: 835–43.
- 813 56 Gough E, Shaikh H, Manges AR. Systematic Review of Intestinal  
814 Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent  
815 *Clostridium difficile* Infection. *Clin Infect Dis* 2011; **53**: 994–1002.
- 816 57 Paramsothy S, Paramsothy R, Rubin DT, *et al.* Faecal Microbiota  
817 Transplantation for Inflammatory Bowel Disease: A Systematic Review  
818 and Meta-analysis. *J Crohns Colitis* 2017; **11**: 1180–99.
- 819 58 Zhao Y, Li X, Zhou Y, *et al.* Safety and Efficacy of Fecal Microbiota  
820 Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim  
821 Results From FMT2017002 Trial. *Front Immunol* 2021; **0**.  
822 DOI:10.3389/fimmu.2021.678476.
- 823 59 Qi X, Li X, Zhao Y, *et al.* Treating Steroid Refractory Intestinal Acute  
824 Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot  
825 Study. *Front Immunol* 2018; **9**. DOI:10.3389/fimmu.2018.02195.
- 826 60 Kao DH, Roach B, Walter J, Lobenberg R, Wong K. A51 EFFECT OF  
827 LYOPHILIZED STERILE FECAL FILTRATE VS LYOPHILIZED DONOR  
828 STOOL ON RECURRENT CLOSTRIDIUM DIFFICILE INFECTION  
829 (RCDI): PRELIMINARY RESULTS FROM A RANDOMIZED, DOUBLE-  
830 BLIND PILOT STUDY. *J Can Assoc Gastroenterol* 2019; **2**: 101–2.
- 831 61 Chehoud C, Dryga A, Hwang Y, *et al.* Transfer of Viral Communities  
832 between Human Individuals during Fecal Microbiota Transplantation. *mBio*  
833 2016; **7**: e00322-16, /mbio/7/2/e00322-16.atom.
- 834 62 Džunková M, Low SJ, Daly JN, Deng L, Rinke C, Hugenholtz P.  
835 Defining the human gut host–phage network through single-cell viral  
836 tagging. *Nat Microbiol* 2019; **4**: 2192–203.
- 837 63 Schwartz M, Gluck M, Koon S. Norovirus Gastroenteritis After Fecal  
838 Microbiota Transplantation for Treatment of *Clostridium difficile* Infection  
839 Despite Asymptomatic Donors and Lack of Sick Contacts. *Am J*  
840 *Gastroenterol* 2013; **108**: 1367–1367.
- 841 64 Mukhopadhyaya I, Segal JP, Carding SR, Hart AL, Hold GL. The gut  
842 virome: the ‘missing link’ between gut bacteria and host immunity? *Ther*  
843 *Adv Gastroenterol* 2019; **12**: 1756284819836620.
- 844 65 Reyes A, Wu M, McNulty NP, Rohwer FL, Gordon JI. Gnotobiotic  
845 mouse model of phage-bacterial host dynamics in the human gut. *Proc*  
846 *Natl Acad Sci* 2013; **110**: 20236–41.

- 847 66 Hsu BB, Gibson TE, Yeliseyev V, *et al.* Dynamic Modulation of the Gut  
848 Microbiota and Metabolome by Bacteriophages in a Mouse Model. *Cell*  
849 *Host Microbe* 2019; **25**: 803-814.e5.
- 850 67 Colavecchio A, Cadieux B, Lo A, Goodridge LD. Bacteriophages  
851 Contribute to the Spread of Antibiotic Resistance Genes among  
852 Foodborne Pathogens of the Enterobacteriaceae Family – A Review. *Front*  
853 *Microbiol* 2017; **8**: 1108.
- 854 68 Feiner R, Argov T, Rabinovich L, Sigal N, Borovok I, Herskovits AA. A  
855 new perspective on lysogeny: prophages as active regulatory switches of  
856 bacteria. *Nat Rev Microbiol* 2015; **13**: 641–50.
- 857 69 Wagner PL, Waldor MK. Bacteriophage Control of Bacterial Virulence.  
858 *Infect Immun* 2002; **70**: 3985–93.
- 859 70 Tetz G, Tetz V. Bacteriophage infections of microbiota can lead to  
860 leaky gut in an experimental rodent model. *Gut Pathog* 2016; **8**: 33.
- 861 71 Sweere JM, Van Belleghem JD, Ishak H, *et al.* Bacteriophage trigger  
862 antiviral immunity and prevent clearance of bacterial infection. *Science*  
863 2019; **363**: eaat9691.
- 864 72 Campbell DE, Ly LK, Ridlon JM, Hsiao A, Whitaker RJ, Degan PH.  
865 Infection with Bacteroides Phage BV01 Alters the Host Transcriptome and  
866 Bile Acid Metabolism in a Common Human Gut Microbe. *Cell Rep* 2020;  
867 **32**: 108142.
- 868 73 Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut  
869 microbiome. *Curr Opin Gastroenterol* 2014; **30**: 332–8.
- 870 74 Molinero N, Ruiz L, Sánchez B, Margolles A, Delgado S. Intestinal  
871 Bacteria Interplay With Bile and Cholesterol Metabolism: Implications on  
872 Host Physiology. *Front Physiol* 2019; **10**: 185.
- 873 75 Barr JJ, Auro R, Furlan M, *et al.* Bacteriophage adhering to mucus  
874 provide a non-host-derived immunity. *Proc Natl Acad Sci* 2013; **110**:  
875 10771–6.
- 876 76 Dufour N, Delattre R, Chevallereau A, Ricard J-D, Debarbieux L.  
877 Phage Therapy of Pneumonia Is Not Associated with an Overstimulation of  
878 the Inflammatory Response Compared to Antibiotic Treatment in Mice.  
879 *Antimicrob Agents Chemother* 2019; **63**: e00379-19,  
880 [/aac/63/8/AAC.00379-19.atom](https://doi.org/10.1128/AAC.00379-19).
- 881 77 Federici S, Nobs SP, Elinav E. Phages and their potential to modulate  
882 the microbiome and immunity. *Cell Mol Immunol* 2021; **18**: 889–904.
- 883 78 Liu L, Gong T, Tao W, *et al.* Commensal viruses maintain intestinal  
884 intraepithelial lymphocytes via noncanonical RIG-I signaling. *Nat Immunol*  
885 2019; **20**: 1681–91.

- 886 79 Neil JA, Matsuzawa-Ishimoto Y, Kernbauer-Hölzl E, *et al.* IFN-I and IL-  
887 22 mediate protective effects of intestinal viral infection. *Nat Microbiol*  
888 2019; **4**: 1737–49.
- 889 80 Campbell DE, Baldrige MT. Enteric viruses seize their  
890 immunomodulatory niche. *Cell Host Microbe* 2021; **29**: 858–61.
- 891 81 Ingle H, Lee S, Ai T, *et al.* Viral complementation of immunodeficiency  
892 confers protection against enteric pathogens via interferon- $\lambda$ . *Nat Microbiol*  
893 2019; **4**: 1120–8.
- 894 82 Clemente JC, Ursell LK, Parfrey LW, Knight R. The Impact of the Gut  
895 Microbiota on Human Health: An Integrative View. *Cell* 2012; **148**: 1258–  
896 70.
- 897 83 Sun Y, Zuo T, Cheung CP, *et al.* Population-level configurations of gut  
898 mycobiome across six ethnicities in urban and rural China.  
899 *Gastroenterology* 2020; published online Sept.  
900 DOI:10.1053/j.gastro.2020.09.014.
- 901 84 Underhill DM, Iliev ID. The mycobiota: interactions between  
902 commensal fungi and the host immune system. *Nat Rev Immunol* 2014;  
903 **14**: 405–16.
- 904 85 Santus W, Devlin JR, Behnsen J. Crossing Kingdoms: How the  
905 Mycobiota and Fungal-Bacterial Interactions Impact Host Health and  
906 Disease. *Infect Immun* 2021; **89**: e00648-20, /iai/89/4/IAI.00648-20.atom.
- 907 86 van Tilburg Bernardes E, Pettersen VK, Gutierrez MW, *et al.* Intestinal  
908 fungi are causally implicated in microbiome assembly and immune  
909 development in mice. *Nat Commun* 2020; **11**: 2577.
- 910 87 Zhang I, Pletcher SD, Goldberg AN, Barker BM, Cope EK. Fungal  
911 Microbiota in Chronic Airway Inflammatory Disease and Emerging  
912 Relationships with the Host Immune Response. *Front Microbiol* 2017; **8**.  
913 DOI:10.3389/fmicb.2017.02477.
- 914 88 Fan D, Coughlin LA, Neubauer MM, *et al.* Activation of HIF-1 $\alpha$  and LL-  
915 37 by commensal bacteria inhibits *Candida albicans* colonization. *Nat Med*  
916 2015; **21**: 808–14.
- 917 89 Sokol H, Leducq V, Aschard H, *et al.* Fungal microbiota dysbiosis in  
918 IBD. *Gut* 2017; **66**: 1039–48.
- 919 90 Das A, O’Herlihy E, Shanahan F, O’Toole PW, Jeffery IB. The fecal  
920 mycobiome in patients with Irritable Bowel Syndrome. *Sci Rep* 2021; **11**:  
921 124.
- 922 91 Wheeler ML, Limon JJ, Bar AS, *et al.* Immunological Consequences of  
923 Intestinal Fungal Dysbiosis. *Cell Host Microbe* 2016; **19**: 865–73.

- 924 92 Liguori G, Lamas B, Richard ML, *et al.* Fungal Dysbiosis in Mucosa-  
925 associated Microbiota of Crohn's Disease Patients. *J Crohns Colitis* 2016;  
926 **10**: 296–305.
- 927 93 Standaert-Vitse A, Sendid B, Joossens M, *et al.* *Candida albicans*  
928 colonization and ASCA in familial Crohn's disease. *Am J Gastroenterol*  
929 2009; **104**: 1745–53.
- 930 94 Kumamoto CA. Inflammation and gastrointestinal *Candida*  
931 colonization. *Curr Opin Microbiol* 2011; **14**: 386–91.
- 932 95 Li M, Li C, Wu X, *et al.* Microbiota-driven interleukin-17 production  
933 provides immune protection against invasive candidiasis. *Crit Care* 2020;  
934 **24**: 268.
- 935 96 Matsuo K, Haku A, Bi B, *et al.* Fecal microbiota transplantation  
936 prevents *Candida albicans* from colonizing the gastrointestinal tract.  
937 *Microbiol Immunol* 2019; **63**: 155–63.
- 938 97 Wu X, Cui B-T, Zhang F-M. Washed microbiota transplantation for the  
939 treatment of recurrent fungal infection in a patient with ulcerative colitis.  
940 *Chin Med J (Engl)* 2021; **134**: 741–2.
- 941 98 Ianiro G, Murri R, Sciumè GD, *et al.* Incidence of Bloodstream  
942 Infections, Length of Hospital Stay, and Survival in Patients With Recurrent  
943 *Clostridioides difficile* Infection Treated With Fecal Microbiota  
944 Transplantation or Antibiotics: A Prospective Cohort Study. *Ann Intern Med*  
945 2019; **171**: 695.
- 946 99 Botschuijver S, Roeselers G, Levin E, *et al.* Intestinal Fungal  
947 Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With  
948 Irritable Bowel Syndrome and Rats. *Gastroenterology* 2017; **153**: 1026–39.
- 949 100 Johnsen PH, Hilpüsch F, Cavanagh JP, *et al.* Faecal microbiota  
950 transplantation versus placebo for moderate-to-severe irritable bowel  
951 syndrome: a double-blind, randomised, placebo-controlled, parallel-group,  
952 single-centre trial. *Lancet Gastroenterol Hepatol* 2018; **3**: 17–24.
- 953 101 van der Velden WJFM, Netea MG, de Haan AFJ, Huls GA, Donnelly  
954 JP, Blijlevens NMA. Role of the Mycobiome in Human Acute Graft-versus-  
955 Host Disease. *Biol Blood Marrow Transplant* 2013; **19**: 329–32.
- 956 102 Guastalegname M, Russo A, Falcone M, Giuliano S, Venditti M.  
957 Candidemia Subsequent to Severe Infection Due to *Clostridium difficile*: Is  
958 There a Link? *Clin Infect Dis* 2013; **57**: 772–4.
- 959 103 Limon JJ, Tang J, Li D, *et al.* *Malassezia* Is Associated with Crohn's  
960 Disease and Exacerbates Colitis in Mouse Models. *Cell Host Microbe*  
961 2019; **0**. DOI:10.1016/j.chom.2019.01.007.
- 962 104 Dotson JL, Crandall W, Mousa H, *et al.* Presentation and outcome of  
963 histoplasmosis in pediatric inflammatory bowel disease patients treated

- 964 with antitumor necrosis factor alpha therapy: A case series: *Inflamm Bowel*  
965 *Dis* 2011; **17**: 56–61.
- 966 105 Iliev ID, Funari VA, Taylor KD, *et al.* Interactions Between Commensal  
967 Fungi and the C-Type Lectin Receptor Dectin-1 Influence Colitis. *Science*  
968 2012; **336**: 1314–7.
- 969 106 Drewniak A, Gazendam RP, Tool ATJ, *et al.* Invasive fungal infection  
970 and impaired neutrophil killing in human CARD9 deficiency. *Blood* 2013;  
971 **121**: 2385–92.
- 972 107 Glocker E-O, Hennigs A, Nabavi M, *et al.* A Homozygous *CARD9*  
973 Mutation in a Family with Susceptibility to Fungal Infections. *N Engl J Med*  
974 2009; **361**: 1727–35.
- 975 108 Seelbinder B, Chen J, Brunke S, *et al.* Antibiotics create a shift from  
976 mutualism to competition in human gut communities with a longer-lasting  
977 impact on fungi than bacteria. *Microbiome* 2020; **8**: 133.
- 978 109 Ordonez ME, Farraye FA, Di Palma JA. Endemic Fungal Infections in  
979 Inflammatory Bowel Disease Associated with Anti-TNF Antibody Therapy:  
980 *Inflamm Bowel Dis* 2013; **19**: 2490–500.
- 981 110 Lam S, Zuo T, Ho M, Chan FKL, Chan PKS, Ng SC. Review article:  
982 fungal alterations in inflammatory bowel diseases. *Aliment Pharmacol Ther*  
983 2019; **50**: 1159–71.
- 984 111 Iliev ID, Leonardi I. Fungal dysbiosis: immunity and interactions at  
985 mucosal barriers. *Nat Rev Immunol* 2017; **17**: 635–46.
- 986 112 Jiang TT, Shao T-Y, Ang WXC, *et al.* Commensal Fungi Recapitulate  
987 the Protective Benefits of Intestinal Bacteria. *Cell Host Microbe* 2017; **22**:  
988 809-816.e4.
- 989 113 Leonardi I, Li X, Semon A, *et al.* CX3CR1+ mononuclear phagocytes  
990 control immunity to intestinal fungi. *Science* 2018; **359**: 232–6.
- 991 114 Li X, Leonardi I, Semon A, *et al.* Response to Fungal Dysbiosis by  
992 Gut-Resident CX3CR1+ Mononuclear Phagocytes Aggravates Allergic  
993 Airway Disease. *Cell Host Microbe* 2018; **24**: 847-856.e4.
- 994 115 Zhu L-L, Zhao X-Q, Jiang C, *et al.* C-Type Lectin Receptors Dectin-3  
995 and Dectin-2 Form a Heterodimeric Pattern-Recognition Receptor for Host  
996 Defense against Fungal Infection. *Immunity* 2013; **39**: 324–34.
- 997 116 Wevers BA, Kaptein TM, Zijlstra-Willems EM, *et al.* Fungal  
998 Engagement of the C-Type Lectin Mincle Suppresses Dectin-1-Induced  
999 Antifungal Immunity. *Cell Host Microbe* 2014; **15**: 494–505.
- 1000 117 Netea MG, Joosten LAB, van der Meer JWM, Kullberg B-J, van de  
1001 Veerdonk FL. Immune defence against *Candida* fungal infections. *Nat Rev*  
1002 *Immunol* 2015; **15**: 630–42.




- 1003 118 Malik A, Sharma D, Malireddi RKS, *et al.* SYK-CARD9 Signaling Axis  
1004 Promotes Gut Fungi-Mediated Inflammasome Activation to Restrict Colitis  
1005 and Colon Cancer. *Immunity* 2018; **49**: 515-530.e5.
- 1006 119 Borghi M, De Luca A, Puccetti M, *et al.* Pathogenic NLRP3  
1007 Inflammasome Activity during Candida Infection Is Negatively Regulated  
1008 by IL-22 via Activation of NLRC4 and IL-1Ra. *Cell Host Microbe* 2015; **18**:  
1009 198–209.
- 1010 120 Netea MG. Immune sensing of Candida albicans requires cooperative  
1011 recognition of mannans and glucans by lectin and Toll-like receptors. *J*  
1012 *Clin Invest* 2006; **116**: 1642–50.
- 1013 121 Izabella M, Marcin U. Gut Mycobiota and Fungal Metabolites in  
1014 Human Homeostasis. *Curr Drug Targets* 2019; **20**: 232–40.
- 1015 122 Mason KL, Erb Downward JR, Mason KD, *et al.* Candida albicans and  
1016 Bacterial Microbiota Interactions in the Cecum during Recolonization  
1017 following Broad-Spectrum Antibiotic Therapy. *Infect Immun* 2012; **80**:  
1018 3371–80.
- 1019 123 Erb Downward JR, Falkowski NR, Mason KL, Muraglia R, Huffnagle  
1020 GB. Modulation of Post-Antibiotic Bacterial Community Reassembly and  
1021 Host Response by Candida albicans. *Sci Rep* 2013; **3**: 2191.
- 1022 124 Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C.  
1023 Saccharomyces boulardii protease inhibits Clostridium difficile toxin A  
1024 effects in the rat ileum. *Infect Immun* 1996; **64**: 5225–32.
- 1025 125 Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C.  
1026 Saccharomyces boulardii Protease Inhibits the Effects of Clostridium  
1027 difficile Toxins A and B in Human Colonic Mucosa. *Infect Immun* 1999; **67**:  
1028 302–7.
- 1029 126 Gedek. Adherence of Escherichia coli serogroup O 157 and the  
1030 Salmonella Typhimurium mutant DT 104 to the surface of Saccharomyces  
1031 boulardii. *Mycoses* 1999; **42**: 261–4.
- 1032 127 Pontier-Bres R, Munro P, Boyer L, *et al.* Saccharomyces boulardii  
1033 Modifies Salmonella Typhimurium Traffic and Host Immune Responses  
1034 along the Intestinal Tract. *PLoS ONE* 2014; **9**.  
1035 DOI:10.1371/journal.pone.0103069.
- 1036 128 Sovran B, Planchais J, Jegou S, *et al.* Enterobacteriaceae are  
1037 essential for the modulation of colitis severity by fungi. *Microbiome* 2018;  
1038 **6**. DOI:10.1186/s40168-018-0538-9.
- 1039 129 Jawhara S, Poulain D. Saccharomyces boulardii decreases  
1040 inflammation and intestinal colonization by Candida albicans in a mouse  
1041 model of chemically-induced colitis. *Med Mycol* 2007; **45**: 691–700.

1042 130 Sivignon A, de Vallée A, Barnich N, *et al.* *Saccharomyces cerevisiae*  
1043 CNCM I-3856 Prevents Colitis Induced by AIEC Bacteria in the Transgenic  
1044 Mouse Model Mimicking Crohn's Disease: *Inflamm Bowel Dis* 2015; **21**:  
1045 276–86.

1046

1047

1048




1049

1050 Figure 1. Composition and function of the gut virome. A. The composition of human gut virome and factors influencing its composition. B.


1051 Functions of the gut virome on the host.

1052

A



B



1053

1054 Figure 2. Composition and function of the gut mycobiome. A. The composition of human gut mycobiome and factors influencing its  
 1055 composition. B. Functions of the gut mycobiome on the host.

1056

1057

1058

1059

Table 1. Summary of human studies investigating FMT and gut virome/mycobiome

Indication	Number of study subjects	Type	Methodology	Treatment outcome in association with gut virome/mycobiome alterations	Reference
CDI	N=44	Randomized Controlled Trial	Faecal virome and bacteriome were profiled in association with treatment outcome	<i>Caudovirales</i> derived from the donors with increased richness displayed responsiveness	7
	N=55	Randomized Controlled Trial	Faecal mycobiome and bacteriome were profiled in association with treatment outcome	High abundances of <i>Candida albicans</i> in donor or recipients led to failure of FMT; FMT decreased <i>Candida albicans</i> abundance	8
	N=9	Pilot-study	Analysis in the metagenome, prophage- and CRISPR-based bacteriophage association and gene functions of the bacteriome and virome after FMT treatment	Successful FMT resulted in functional restoration in the bacteriome and virome resembling donors' profiles. A negative correlation between <i>Microviridae</i> and <i>Proteobacteria</i> was found before and after FMT	35
	N=1	Case-study	Longitudinal investigations up to 42 months on patient's bacteriome and virome after a successful FMT	Bacteriome and virome in the patient resembled the donor's profile long-term; low phage abundance is associated with a 'healthy' virome profile	47
	N=14	Pilot-study	Investigations up to 12 months on the viral transfer from 3 donors to 14 patients	A successful FMT was associated with durable virome alterations up to 12 months in recipients	46
IBD	N=39	Randomized Controlled Trial	Faecal mycobiome was profiled in association with treatment outcome	FMT responders showed lower faecal <i>Candida albicans</i> abundances and anti- <i>Candida</i> antibody levels after FMT	9
	N=9	Pilot-study	Analysis in the UC faecal virome and its association with induction of clinical and endoscopic remission	FMT responders showed lower baseline eukaryotic virome richness	44
GvHD	N=1	Case-study	Faecal virome, mycobiome and bacteriome were profiled longitudinally in one patient treated with 4-dose FMT	Decreased faecal fungal diversity after serial FMTs, while virome maintained stable after FMT; relative abundance of Torque teno viruses was decreased, whereas <i>Caudovirales</i> bacteriophages was increased in faeces after FMT	12